Tata Elxsi Launches a Global Technology Centre for Medical Devices from Bayer

Pune:  Tata Elxsi, a global leader in design and technology services, today announced the inauguration of the ‘Bayer Development Centre in Radiology’ at Tata Elxsi, Pune, India. The centre is designed to co-develop with Bayer, a leader in key areas of Radiology, advanced radiology devices and technology that enable early and accurate diagnosis and treatment of critical illnesses, supporting Bayer’s global mission to bring innovative, safe, and compliant solutions to patients and clinical staff worldwide.

This centre will provide a wide range of engineering for complex radiology devices, with an initial focus on Molecular Imaging. The facility’s integrated approach, which combines design, development, and validation, the centre will help accelerate time-to-market, enhance cost efficiency, and help deliver new technology to market fast, efficiently, and at an optimized cost, while meeting highest regulatory compliance standards.

This collaboration leverages Tata Elxsi’s healthcare engineering expertise and the strength of the Tata and India ecosystems—enabling access to advanced labs, regulatory partnerships, and specialised technology talent. This creates a scalable foundation for innovation and strengthens Bayer’s ability to deliver radiology solutions across multiple geographies, including the US and EU.

Dr. Konstanze Diefenbach, Head of Research & Development, Radiology, Bayer, commented: “Bayer is committed to innovative products and high-quality services in diagnostic imaging, and device innovation plays a critical role in delivering precision and safety in patient care. This new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer.”

Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This centre is more than an engineering hub—it is where Bayer’s radiology vision meets Tata Elxsi’s design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability.”

Related Posts

Pharma companies in a flux over Trump’s 200% tariff move on generics

India’s $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face tariffs of 100% from Aug…

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

New Delhi: A joint operation by the Delhi Police Crime Branch, the Central Drugs Standard Control Organisation (CDSCO) and the Gautam Buddha Nagar District Drug Department uncovered a suspected illegal…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

CDSCO declares 159 drug samples as NSQs in June

CDSCO declares 159 drug samples as NSQs in June